Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design.

Cancer Chemother Pharmacol 2010 Sep 11;66(4):797-805. Epub 2010 Mar 11.

Cancer Metastasis Research Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, Korea.

Purpose: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment.

Methods: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles.

Results: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P < 0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifth-line. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first- to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment.

Conclusions: Clinical trials may be feasible in second- or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1295-zDOI Listing
September 2010
1 Read

Publication Analysis

Top Keywords

salvage chemotherapy
16
gastric cancer
12
trial design
8
advanced gastric
8
chemotherapy group
8
progression-free survival
8
supportive care
8
clinical trials
8
prognostic factors
8
sequential salvage
8
performance status
8
chemotherapy
8
121 months
8
months
5
salvage
5
126 109
4
47% second-line
4
109 disease
4
chemotherapy 47%
4
disease control
4

Altmetric Statistics

References

(Supplied by CrossRef)

DM Parkin et al.
CA Cancer J Clin 1999

HR Shin et al.
Cancer Res Treat 2004

M D’Angelica et al.
Ann Surg 2004

S Kim et al.
Int J Radiat Oncol Biol Phys 2005

B Glimelius et al.
Ann Oncol 1997

S Pyrhönen et al.
Br J Cancer 1995

E Cutsem Van et al.
J Clin Oncol 2006

YK Kang et al.
Ann Oncol 2009

D Cunningham et al.
N Engl J Med 2008

W Koizumi et al.
Lancet Oncol 2008

F Marinis de et al.
Oncologist 2008

Similar Publications